NMD Pharma A/S | LinkedIn
NMD Pharma
Management — NMD Pharma
Labiotech.eu on Twitter: "NMD Pharma, from @AarhusUni, is willing to tackle Neuromuscular Transmission Disorders #BioEquity2016… "
NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
Big deal: NMD flexes series A muscles - Global University Venturing
Management — NMD Pharma
Denmark in New York on Twitter: "#DKBIO17 is "a great opportunity for us to broaden our scope and look for investors.” - Thomas H. Pedersen, CEO, NMD Pharma… https://t.co/AUeO5JqgX6"
NMD Pharma
NMD Pharma - Capnova
Company Presentation
NMD Pharma brænder 41 mio. kr. af sin kæmpeinvestering
NMD Pharma Initiates a Combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis
NMD Pharma begins first clinical trial: "Our entire team can be enormously proud"
Company Presentation
NMD Pharma - PIR International
NMD Pharma company information, funding & investors | Dealroom.co
NMD Pharma raises €38M (~USD 47 Million) SERIES A Financing to Advance Treatments of Neuromuscular Disorders
Contact — NMD Pharma
Tunge pengetanke klar til nye investeringer i biotekselskab fra Aarhus
NMD Pharma is Strengthening Muscles in Neuromuscular Disorders
